Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

杜皮鲁玛 医学 特应性皮炎 皮肤病科
作者
Margitta Worm,Eric L. Simpson,Diamant Thaçi,Robert Bissonnette,J.‐P. Lacour,Stefan Beissert,Makoto Kawashima,Carlos Ferrándiz,Catherine Smith,Lisa A. Beck,Kuo‐Chen Chan,Zhen Chen,Bolanle Akinlade,Thomas Hultsch,Heribert Staudinger,Abhijit Gadkari,Laurent Eckert,John D. Davis,Manoj Rajadhyaksha,Neil M.H. Graham
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:156 (2): 131-131 被引量:155
标识
DOI:10.1001/jamadermatol.2019.3617
摘要

The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD).To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment.The Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (LIBERTY AD SOLO-CONTINUE) was a randomized, double-blind, phase 3 clinical trial conducted from March 25, 2015, to October 18, 2016, at 185 sites in North America, Europe, Asia, and Japan. Patients with moderate to severe AD who received dupilumab treatment and achieved an Investigator's Global Assessment score of 0 or 1 or 75% improvement in Eczema Area and Severity Index scores (EASI-75) at week 16 in 2 previous dupilumab monotherapy trials (LIBERTY AD SOLO 1 and 2) were rerandomized in SOLO-CONTINUE. After completing SOLO-CONTINUE, patients were followed up for up to 12 weeks or enrolled in an open-label extension. Data were analyzed from December 5 to 12, 2016.High-responding patients treated with dupilumab in SOLO were rerandomized 2:1:1:1 to continue their original regimen of dupilumab, 300 mg, weekly or every 2 weeks or to receive dupilumab, 300 mg, every 4 or 8 weeks or placebo for 36 weeks.Percentage change in EASI score from baseline during the SOLO-CONTINUE trial, percentage of patients with EASI-75 at week 36, and safety.Among the 422 patients (mean [SD] age, 38.2 [14.5] years; 227 [53.8%] male), continuing dupilumab treatment once weekly or every 2 weeks maintained optimal efficacy, with negligible change in percent EASI improvement from SOLO 1 and 2 baseline during the SOLO-CONTINUE trial (-0.06%; P < .001 vs placebo); percent change with the other regimens dose-dependently worsened (dupilumab every 4 weeks, -3.84%; dupilumab every 8 weeks, -6.84%; placebo, -21.67%). More patients taking dupilumab weekly or every 2 weeks (116 of 162 [71.6%]; P < .001 vs placebo) maintained EASI-75 response than those taking dupilumab every 4 weeks (49 of 84 [58.3%]) or every 8 weeks (45 of 82 [54.9%]) or those taking placebo (24 of 79 [30.4%]). Overall adverse event incidences were 70.7% in the weekly or every 2 weeks group, 73.6% in the every 4 weeks group, 75.0% in the every 8 weeks group, and 81.7% in the placebo group. Treatment groups had similar conjunctivitis rates. Treatment-emergent antidrug antibody incidence was lower with more frequent dupilumab dose regimens (11.3% in the placebo group and 11.7%, 6.0%, 4.3%, and 1.2% in the dupilumab every 8 weeks, every 4 weeks, every 2 weeks, and weekly groups, respectively).In this trial, continued response over time was most consistently maintained with dupilumab administered weekly or every 2 weeks. Longer dosage intervals and placebo resulted in a diminution of response for both continuous and categorical end points. No new safety signals were observed. The approved regimen of 300 mg of dupilumab every 2 weeks is recommended for long-term treatment.ClinicalTrials.gov identifier: NCT02395133.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
肖果完成签到 ,获得积分10
1秒前
哭泣笑柳发布了新的文献求助10
2秒前
CipherSage应助长安采纳,获得10
3秒前
飒飒完成签到,获得积分10
4秒前
RONG完成签到 ,获得积分10
4秒前
落落完成签到,获得积分10
5秒前
Yan完成签到 ,获得积分10
6秒前
6秒前
谨慎的凝丝完成签到 ,获得积分10
7秒前
雨洋完成签到,获得积分10
8秒前
chi完成签到 ,获得积分10
9秒前
还单身的湘完成签到,获得积分10
11秒前
fyjlfy完成签到 ,获得积分10
11秒前
深情安青应助Nayvue采纳,获得10
12秒前
研友_Y59785完成签到,获得积分0
12秒前
Xiaoxiao发布了新的文献求助10
13秒前
初初见你完成签到,获得积分10
20秒前
23秒前
思源应助淡淡月饼采纳,获得20
23秒前
dd完成签到 ,获得积分10
24秒前
Nayvue发布了新的文献求助10
28秒前
未来的幻想完成签到,获得积分10
30秒前
Kvolu29完成签到,获得积分10
31秒前
长理物电强完成签到,获得积分10
32秒前
若安在完成签到,获得积分10
33秒前
完美世界应助潘特采纳,获得10
34秒前
拼搏问薇完成签到 ,获得积分10
34秒前
单薄乐珍完成签到 ,获得积分0
37秒前
张静枝完成签到 ,获得积分10
37秒前
六步郎完成签到,获得积分10
37秒前
啊怙纲完成签到 ,获得积分10
39秒前
量子星尘发布了新的文献求助10
41秒前
scott_zip完成签到 ,获得积分10
42秒前
gxl完成签到,获得积分0
46秒前
xxx完成签到 ,获得积分10
49秒前
49秒前
努力生活的小柴完成签到,获得积分10
51秒前
53秒前
tangyong完成签到,获得积分10
55秒前
长安发布了新的文献求助10
55秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022